I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow

Promises to be a fantastic session! 🌟Delighted PMR is getting the attention it deserves 🌟 2pm GMT/ 9am EST #ACR22 @RheumNow @SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO

Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ

• Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimula…

Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5

• Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As A…

"Less steroid is more" in multiple diseases. Dr. J Kolfenbach #ACR22 @RheumNow

van Nieuwland et al. Comparison US/PET/MRI in GCA. Good specificity but relatively low sensitivity for all. PET best for extra-cranial. MRI/US best for isolated cranial. @RheumNow #ACR22 Abstr#1617 https://t.co/CI3TtxOQJL https://t.co/3pJeGo49Gj

• Direct Comparison of Ultrasound, [18F]Fluorodeoxyglucose-Positron Emission Tomo…

Stamatis et al. MI in systemic vasculitis vs controls. Only difference - less likely to have pre-existing CVD. No significant difference in outcomes - but this may be due to underpowered - see Figures. @RheumNow #ACR22 Abstr#1615 https://t.co/bYtMr1jGXN https://t.co/QABW2GiVFl

• Myocardial Infarction in Patients with Systemic Vasculitis and Population Contr…

#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group @RheumNow https://t.co/iucDK1GpU4

Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf

• Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort - Associati…

Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared to 2nd TNFi following failure of 1st TNFi. @RheumNow #ACR22 Abstr#2149 https://t.co/Er2FKwYdRv https://t.co/uMPSfMkjfa

• Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rhe…

#ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm

"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow

Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp

• Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Resul…

Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs

• Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients …